REQUIP XL
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
REQUIP XL by GSK is non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d 2 and d 3 dopamine receptor subtypes, binding with higher affinity to d 3 than to d 2 or d 4 receptor subtypes. Approved for signs, symptoms of idiopathic parkinson’s disease, the signs. First approved in 2008.
Drug data last refreshed 2d ago
Mechanism of Action
non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 and D 3 dopamine receptor subtypes, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Ropinirole has moderate in vitro affinity for opioid receptors. Ropinirole and…
Indications (3)
Worked on REQUIP XL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.